Skip to main content
Caplight Logo









Talus Bio

Talus Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.talus.bio/

Last Round

Seed

Aug 20, 2024

Est. Valuation

$19.7M

Total Funding Raised

$24.26M

Company Overview

Talus Bio is a biotechnology company that offers a data-enabled drug development platform for small-molecule therapies in oncology, integrating cell processing, high-sensitivity quantitative proteomics, and machine learning analytics to enhance drug discovery through gene regulation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

drug discoverytranscription factorsprotein-protein interactionsundruggable targetsAI drug discoveryfunctional proteomicssmall molecule inhibitorsbiotech platformoncology therapeuticsin silico drug designhit-to-lead optimizationcomputational biologypharma partnershipsAI-first biotechsmall molecule discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Talus Bio Comparables

Compare Talus Bio with similar companies based on industry and business-model similarity.

Talus Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rezo Therapeutics
82%
Flare Therapeutics
77%
Octant
77%

Talus Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 20, 2024
GrantAug 18, 2023
SeedJun 6, 2022
Pre SeedOct 1, 2020

Key People

Founding team and executive leadership

Lindsay Pino

Co-Founder and CTO

Founding Team

Alex Federation

Co-Founder, CEO

Founding Team

Talus Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 17, 2026

    Grew 15% QoQ, from 26 to 30 employees.

  • Apr 25, 2025

    Presented preclinical data on transcription factor therapeutic programs at AACR 2025.

Recent news

Latest coverage and updates

  • receives_financingJul 9, 2026

    Talus Bioscience, Inc. received financing of $1.03M in SBIR R44 grant on Jul 9th '26.

Talus Bio Filings

Explore SEC and related filing metadata, where available.

Talus Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Talus Bio's valuation, stock price, and market status.

Is Talus Bio a public or private company?

Talus Bio is a private company.

What is the current stock price of Talus Bio?

Talus Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Talus Bio worth (valuation)?

Talus Bio's valuation is estimated at $19.7M based on funding round data.

Can I buy Talus Bio stock?

Talus Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Talus Bio's last funding round?

Talus Bio's most recent funding round was Seed+ on August 20, 2024.

Who are the main investors in Talus Bio?

Key investors in Talus Bio include NFX, Two Bear Capital.

Will Talus Bio IPO soon?

No public IPO plans have been announced for Talus Bio.

How can I track Talus Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Talus Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range26
Year Founded2020
Last FundingAug 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?